2-aminoethanol;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-aminoethanol;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
• 化学式: C₄₆H₄₇N₆O₈PolS₂
• 分子量: 619.7
• InChiKey: FOOAEOOXHSQPBD-CNZCJKERSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.25
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  158
• 氢给体数：
  6
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-aminoethanol;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid 在 potassium carbonate 、 苯硫酚 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  [EN] POLYAMINE ANALOGS THAT ACTIVATE ANTIZYME FRAMESHIFTING
  [FR] ANALOGUES DE POLYAMINE QUI ACTIVENT LE DEPHASAGE ANTI-ENZYME

  摘要：

  本发明提供了新型多胺化合物的合成及其在药物、化妆品或农业应用中的使用。这些多胺化合物能够诱导抗酶的产生，从而下调鸟氨酸脱羧酶（ODC）产生的多胺化合物以及相应的多胺转运蛋白对多胺的运输。这些化合物将优先独立于多胺转运蛋白进入细胞。作为药物，这些化合物被用于治疗与细胞增殖有关的任何疾病，包括但不限于癌症。

  公开号：

  WO2005105729A1
• 作为产物：
  描述：

  C.I.酸性橙108 、 阿托伐他汀 以 乙腈 为溶剂， 反应 144.0h， 生成 2-aminoethanol;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
  参考文献：
  名称：

  [EN] SALT FORMS OF ATORVASTATIN
  [FR] FORMES SALINES D'ACIDE [R-(R*, R*)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE

  摘要：

  公开号：

  WO2005105738A3

文献信息

• Drug or Pharmaceutical Compounds and a Preparation Thereof
  申请人：Krishnan Ramu

  公开号：US20080200533A1

  公开（公告）日：2008-08-21

  The administration of pharmaceuticals of drugs which are having less solubility, lower bioavailability, lower bioabsorbability, less rate of absorption has become a big challenge in day to day life. Therefore an attempt has been made to prepare a complex modified form of the said pharmaceutical or drug such that the modified complex drugs or pharmaceuticals exhibits the enhanced properties of solubility, bioavailability, bioabsorbability and rate of absorption despite the increased complexity of the molecule. Surprisingly such modification was found to enhance retentivity of the active drug ingredient in the blood. Higher amounts of the active drug ingredient has shown lower toxicity.

  药物管理中，对那些溶解度较低、生物利用度较低、生物吸收率较低、吸收速率较低的药物进行处理已经成为日常生活中的一大挑战。因此，人们尝试制备所述药物或药品的复合改性形式，使得这种改性复合药物或药品展现出增强的溶解度、生物利用度、生物吸收率和吸收速率等性质，尽管分子的复杂性增加。令人惊讶的是，这种修改被发现可以增强活性药物成分在血液中的保留能力。更多量的活性药物成分显示出较低的毒性。
• Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
  申请人：Campeta Anthony Michael

  公开号：US20080188652A1

  公开（公告）日：2008-08-07

  Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hypedlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

  本发明涉及一种[R-(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯氨基)羰基]-1H-吡咯-1-庚酸的新型盐形式，其特征在于其X射线粉末衍射图谱和固态NMR谱。本发明还涉及制备该盐形式的方法和制备药物组合物的方法，该药物组合物可用作治疗高脂血症、高胆固醇血症、骨质疏松症、良性前列腺增生症和阿尔茨海默病的药物。
• Salt Forms of [R-(R*,R*)*rsqb;-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
  申请人：Campeta Anthony Michael

  公开号：US20080171872A1

  公开（公告）日：2008-07-17

  Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

  描述了[R—(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯氨基)羰基]-1H-吡咯-1-庚酸的新型盐形态，其具有X射线粉末衍射图案和固态NMR光谱特征，同时也描述了制备这些盐形态的方法和制备药物组合物的方法，这些药物组合物可用于治疗高脂血症、高胆固醇血症、骨质疏松症、良性前列腺增生和阿尔茨海默病。
• Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-beta, alpha-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-Heptanoic Acid
  申请人：Campeta Anthony Michael

  公开号：US20110172443A1

  公开（公告）日：2011-07-14

  Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

  本文描述了[R—(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯氨基)羰基]-1H-吡咯-1-庚酸的新型盐形态，其特征是其X射线粉末衍射图谱和固态核磁共振光谱，以及制备这些盐形态的方法和药物组合物，可用作治疗高脂血症、高胆固醇血症、骨质疏松症、良性前列腺增生症和阿尔茨海默病的药物。
• Salt forms of [R-(R*,R*)]-2-(4-flurorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
  申请人：Campeta Anthony Michael

  公开号：US20120264934A1

  公开（公告）日：2012-10-18

  Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

  本文介绍了[R—（R*，R*）]-2-（4-氟苯基）-β，δ-双羟基-5-（1-甲基乙基）-3-苯基-4-[(苯基氨基）-羰基]-1H-吡咯-1-庚酸的新型盐形，其具有X射线粉末衍射图谱和固态核磁共振光谱的特征，同时介绍了制备和制药组合物的方法，该组合物可用于治疗高脂血症，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病等疾病。